Risdiplam liquid approved for use in spinal muscular atrophy in the US
Approval of this oral SMN2 splicing modifier was based on data from the FIREFISH and SUNFISH studies. A marketing authorisation application for use in the EU has not yet been made.
Source:
PharmaTimes